Does Rallies show Form 4 insider transactions for COGT?

Yes. Rallies tracks COGT insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is COGT research on Rallies investment advice?

No. Rallies provides research, data, and educational context for COGT. It does not provide personalized investment advice.

COGT (Cogent Biosciences, Inc. Common Stock) Stock Analysis - Insider Trades

Cogent Biosciences, Inc. Common Stock (COGT) is a publicly traded Healthcare sector company. As of May 21, 2026, COGT trades at $33.05 with a market cap of $5.36B and a P/E ratio of -15.19. COGT moved +5.44% today. Year to date, COGT is -3.90%; over the trailing twelve months it is +520.06%. Its 52-week range spans $3.72 to $43.73. Analyst consensus is strong buy with an average price target of $52.10. Rallies surfaces COGT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading COGT stock inside the company?

Recent COGT insider activity includes Fairmount Funds Management LLC sold 7.00M, Fairmount Funds Management LLC sold 3.50M, Kearns Evan sold 65.00K, Green John L. sold 77.00K, and Sachs Jessica sold 82.64K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

COGT Key Metrics

Key financial metrics for COGT
Metric	Value
Price	$33.05
Market Cap	$5.36B
P/E Ratio	-15.19
EPS	$-2.16
Dividend Yield	0.00%
52-Week High	$43.73
52-Week Low	$3.72
Volume	1.54M
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-328.94M
Gross Margin	0.00%

Recent COGT Insider Trades

Fairmount Funds Management LLC sold 7.00M (~$242.62M) on Mar 31, 2026.
Fairmount Funds Management LLC sold 3.50M (~$127.40M) on Jan 22, 2026.
Kearns Evan sold 65.00K (~$2.52M) on Dec 26, 2025.
Green John L. sold 77.00K (~$2.98M) on Dec 26, 2025.
Sachs Jessica sold 82.64K (~$3.20M) on Dec 26, 2025.

Latest COGT News

Cogent Biosciences slips as investors digest Q1 loss and long PDUFA timeline — May 6, 2026
Cogent Biosciences Secures $866M Cash Runway into 2028, Eyes Dual Bezuclastinib Launches — May 5, 2026
Cogent Biosciences rises as bezuclastinib FDA filings near and ASCO catalyst approaches — May 1, 2026
Cogent Biosciences slips as 7M-share Form 144 overhang pressures biotech rally — Apr 29, 2026
Cogent Biosciences dips as Form 144 flags potential 7 million-share resale overhang — Apr 10, 2026

COGT Analyst Consensus

11 analysts cover COGT: 0 strong buy, 9 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $52.10.

Common questions about COGT

Who is trading COGT stock inside the company?: Recent COGT insider activity includes Fairmount Funds Management LLC sold 7.00M, Fairmount Funds Management LLC sold 3.50M, Kearns Evan sold 65.00K, Green John L. sold 77.00K, and Sachs Jessica sold 82.64K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for COGT?: Yes. Rallies tracks COGT insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is COGT research on Rallies investment advice?: No. Rallies provides research, data, and educational context for COGT. It does not provide personalized investment advice.